THC and CBD are the two most abundant active compounds in cannabis, and while they come from the same plant and share a similar chemical backbone, they produce strikingly different effects. THC (delta-9-tetrahydrocannabinol) is the compound responsible for the “high” associated with marijuana. CBD (cannabidiol) does not produce that intoxication, which is a large part of why it has become so popular in wellness products. The differences between them run deeper than just whether you feel stoned, though, affecting everything from how each compound interacts with your brain’s receptors to which medical conditions they treat and how they show up on a drug test.
How THC and CBD Interact With Your Body
Both THC and CBD work through the endocannabinoid system, a network of receptors and signaling molecules that your body uses to regulate pain, mood, appetite, immune responses, and more. The two main receptors in this system are called CB1 and CB2. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are more common in immune cells and peripheral tissues.
THC binds directly to the CB1 receptor in the brain, fitting into the same pocket where your body’s own endocannabinoids normally dock. It acts as a partial agonist there, meaning it activates the receptor but not as fully as the body’s own molecules would.1PubMed Central. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin That partial activation of CB1 is what produces the euphoria, altered time perception, and appetite stimulation people associate with marijuana. A 2025 study shed light on why THC behaves this way: the molecule can shift between two binding pockets within the CB1 receptor, toggling the receptor on and off rather than locking it fully into an active state.2iScience. How THC works: Explaining ligand affinity for, and partial agonism of, cannabinoid receptor 1
CBD, by contrast, does not strongly bind to CB1 or CB2. Instead, it works through a broader and less well-defined set of targets, influencing inflammation, oxidative stress, pain signaling, and neural excitability through multiple pathways at once.3PubMed Central. Molecular and Cellular Mechanisms of Action of Cannabidiol This scattershot mechanism is part of why CBD research has been both promising and hard to pin down: it seems to nudge many systems a little rather than slamming one receptor hard the way THC does.
The Psychoactive Divide
The most obvious practical difference between THC and CBD is intoxication. THC makes you high; CBD does not. But the distinction goes further than just euphoria versus sobriety. THC acutely impairs several cognitive functions, particularly memory. In one study, memory accuracy declined in a dose-dependent manner as blood THC levels rose, with participants using high-THC strains performing significantly worse on a verbal recognition task after use.4PubMed Central. Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study CBD on its own showed no relationship to memory performance whatsoever in the same study.
A double-blind, placebo-controlled trial in healthy volunteers found a similar pattern across a wider set of measures. THC reduced cognitive processing speed, impaired attention, and altered emotional states related to activity levels and sociability. CBD given alone had no effect on emotion, cognition, or attention at all.5PubMed Central. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers Interestingly, pre-treating with CBD before administering THC did not block THC’s cognitive effects in that single-dose experiment. The idea that CBD reliably “cancels out” a THC high is more complicated than many people assume.
That said, the broader evidence is not so clean-cut. A review of the research literature found that some studies do show CBD can prevent certain THC-induced cognitive impairments when the two are taken together, and the two compounds show opposite effects on brain activation patterns during cognitive tasks.6PubMed Central. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition The degree to which CBD moderates THC likely depends on the ratio, the timing, and individual biology. But the safe takeaway is that strains or products high in THC will impair your thinking in ways that CBD products will not.
Anxiety and Mood
Anxiety is where THC and CBD diverge in a way that catches many users off guard. People often reach for cannabis to calm down, but the two major cannabinoids pull in opposite directions. CBD has shown anxiolytic (anxiety-reducing) effects in both animal and human studies at acute doses, without producing more anxiety at higher amounts.7PubMed Central. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties THC, on the other hand, commonly increases anxiety, and this effect tends to get worse at higher doses.
This means that the experience you have with a cannabis product depends enormously on its cannabinoid profile. A CBD oil or hemp flower may genuinely ease nervousness for some people. A high-THC edible or concentrate could trigger a panic attack, especially in someone predisposed to anxiety or unfamiliar with the sensation. If relaxation is the goal, the THC-to-CBD ratio matters far more than the product’s marketing.
Medical Uses of THC
THC has the longest track record in prescription medicine, primarily through synthetic or standardized forms like dronabinol and nabilone. The strongest evidence supports its use against chemotherapy-induced nausea and vomiting: a meta-analysis of seven randomized controlled trials found that patients taking cannabinoids were roughly three and a half times more likely to achieve relief from nausea and vomiting compared with placebo.8PubMed Central. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms
Evidence for pain relief is less definitive. A pooled analysis of 15 randomized trials found that more patients taking cannabinoids achieved at least a 30% pain reduction compared with placebo, but larger and longer trials within that set tended to find no benefit. When cannabinoids do help with pain, the effect appears to be modest and is most relevant for neuropathic pain rather than acute or general pain. Spasticity, particularly in people with multiple sclerosis, is another area where THC-based treatments show a signal: patients were more likely to report an overall improvement, though the evidence did not consistently reach statistical significance across all outcome measures.
THC’s appetite-stimulating effects are also used clinically for wasting conditions, including HIV-associated weight loss. This is the “munchies” effect put to therapeutic use, and it remains one of the few appetite-stimulating options that does not require hormonal intervention.
Medical Uses of CBD
CBD’s clearest medical success story is in severe childhood epilepsy. Epidiolex, a pharmaceutical-grade CBD solution, became the first cannabis-derived drug approved by the FDA, specifically for Dravet syndrome and Lennox-Gastaut syndrome, two forms of drug-resistant epilepsy that begin in early childhood and respond poorly to conventional medications.
The pivotal trial in Dravet syndrome showed that children receiving CBD saw their monthly convulsive seizure count drop from about 12 to roughly 6, while the placebo group barely changed.9PubMed. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome A meta-analysis pooling data from multiple trials confirmed this benefit, finding that patients on CBD were about 69% more likely to achieve at least a 50% reduction in seizure frequency compared with placebo.10PubMed. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety Reviews of trial data across different patient subgroups have found the efficacy to be consistent and the safety profile manageable, with some patients even reaching seizure freedom.11PubMed Central. The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials
Beyond epilepsy, CBD is being investigated for anxiety disorders, chronic pain, inflammatory conditions, and even some psychiatric disorders. The preclinical evidence is broad: CBD appears to influence inflammation, oxidative damage, cell survival, pain pathways, and vascular function.3PubMed Central. Molecular and Cellular Mechanisms of Action of Cannabidiol But “being investigated” is doing heavy lifting in that sentence. For most of these conditions, the evidence in humans is still preliminary. Epilepsy remains the only area with strong enough clinical trial data to support regulatory approval.
How You Take Them Changes What They Do
Whether you inhale, swallow, or apply a cannabinoid topically changes how quickly it works, how strong the effects are, and how long they last. This applies to both THC and CBD, and the pharmacokinetic differences are more dramatic than many consumers realize.
When CBD is vaporized, blood levels peak almost immediately and drop off relatively quickly. When the same amount is swallowed, peak blood levels take about four hours to arrive but the compound stays detectable for longer.12Journal of Analytical Toxicology. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products Vaporizing CBD from whole cannabis flower (which also contains terpenes and trace amounts of other cannabinoids) produced higher peak CBD concentrations in blood than vaporizing pure CBD at the same dose. This aligns with the widespread claim in the cannabis industry that whole-plant products deliver cannabinoids more effectively, though the mechanisms behind that observation are still debated.
Urinary data tells a complementary story. In a controlled study, oral CBD produced higher urinary CBD concentrations than vaporized CBD at the same dose, and the time to peak concentration in urine was significantly longer after oral administration, reflecting the slower absorption through the gut.13Journal of Analytical Toxicology. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration These timing differences matter practically: if you need rapid symptom relief, inhalation works faster. If you want sustained effects over hours, an oral product makes more sense, though you will need patience waiting for it to kick in.
THC follows broadly similar kinetics: inhalation produces a rapid peak and shorter duration, while edibles produce a delayed but sometimes more intense and longer-lasting high. This delayed onset of oral THC is a common source of accidental overconsumption when people eat more because they “don’t feel anything yet.”
Drug Interactions to Watch
Both THC and CBD interfere with the liver enzymes responsible for processing many common medications. These enzymes, part of the CYP450 family, metabolize a wide range of drugs including blood thinners, seizure medications, antidepressants, and immunosuppressants. Both cannabinoids inhibit several of these enzymes, but CBD is the more potent inhibitor.14PubMed. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization
A systematic review specifically identified CBD as a consistent inhibitor of CYP3A4, CYP2C9, and CYP2C19, three of the most important drug-metabolizing enzymes.15PubMed. The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review In plain terms, if you take CBD alongside a medication that relies on those enzymes to break it down, the drug can build up to higher-than-intended levels in your blood. This is the same type of interaction that grapefruit juice causes, and it is the reason doctors monitoring patients on Epidiolex sometimes need to adjust the doses of concurrent seizure medications. If you take prescription drugs and are considering any cannabinoid product, a conversation with your pharmacist or prescriber is worth having.
The Delta-8 Wildcard
You may have seen “delta-8 THC” products at gas stations and smoke shops, marketed as a legal and milder alternative to regular marijuana. Delta-8-THC is an isomer of the more familiar delta-9-THC, meaning it has the same atoms arranged in a slightly different configuration. Its pharmacology is very similar: delta-8 is also a partial agonist at the CB1 receptor and produces cannabimimetic effects in both animals and humans. It is simply less potent, likely because it binds the CB1 receptor less strongly than delta-9.16PubMed. Review of delta-8-tetrahydrocannabinol (Δ(8) -THC): Comparative pharmacology with Δ(9) -THC
“Less potent” does not mean “not psychoactive.” Delta-8 will get you high. It will also likely show up on a drug test. Workplace urine assays detect a metabolite called THC-COOH, and research on drug-testing specimens has found that the metabolite concentrations produced by delta-8 and delta-9 are similar enough that the same cutoff thresholds and decision rules apply to both.17Journal of Analytical Toxicology. Prevalence of Δ8-tetrahydrocannabinol carboxylic acid in workplace drug testing So using delta-8 products before a workplace screening is functionally equivalent to using marijuana as far as the test is concerned.
Can CBD Trigger a Positive Drug Test?
Pure CBD itself is not what standard drug tests look for. But the real-world answer is not as simple as “CBD won’t show up.” Many CBD products, especially full-spectrum ones derived from hemp, contain trace amounts of THC. The U.S. 2018 Farm Bill defines hemp as cannabis containing no more than 0.3% total THC on a dry weight basis.18Journal of AOAC INTERNATIONAL. THC Content on a Dry Weight Basis: Implications for Hemp Legality That sounds like almost nothing, but with regular high-dose use of a full-spectrum CBD oil, those trace amounts can accumulate to detectable levels in urine.
Research on workplace drug-testing specimens has also identified rare cases where high concentrations of CBD metabolites like 7-OH-CBD cross-reacted with immunoassay screens, producing a positive result even without significant THC exposure.19Journal of Analytical Toxicology. Prevalence of Cannabidiol, ∆9- and ∆8-Tetrahydrocannabinol and Metabolites in Workplace Drug Testing Urine Specimens This cross-reactivity appears to be uncommon and requires very high CBD metabolite concentrations, but it does mean that no CBD product comes with a genuine guarantee of a clean drug screen. If your job tests for cannabinoids, any cannabis-derived product carries some risk.
What Is Actually in CBD Products
The CBD market has a serious quality-control problem that is worth knowing about regardless of which cannabinoid you are interested in. An analysis of over 200 commercial CBD products found that roughly three out of four deviated from their labeled CBD potency by at least 10%, and about a quarter did not even meet the definition for the type of product claimed on the packaging (for example, labeled “broad spectrum” but containing THC, or labeled “isolate” but containing other cannabinoids). Heavy metals, especially lead, were detected in over 20% of products tested, and residual solvents appeared in the vast majority.20PubMed Central. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples
A separate study of over 500 CBD products found similar inaccuracy: only about 42% of products contained CBD within 10% of what the label stated. Lead was detected in 42% of edible CBD products, mercury in 37%, and arsenic in 28%.21PubMed. Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products While most individual results fell below safety thresholds, the overall picture is one of an industry where you frequently do not get what you pay for. Looking for products that publish third-party lab results (certificates of analysis) is the minimum due diligence, though even that is not foolproof.
From Plant to Active Compound
One detail that surprises many people: the cannabis plant does not actually produce THC or CBD directly. It produces their acidic precursors, THCA and CBDA, which are not psychoactive and have different biological properties. Heat converts these acids into their active forms through a reaction called decarboxylation, which is essentially the loss of a carbon dioxide molecule from the compound.22PubMed Central. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry This happens when you smoke, vape, or bake cannabis. It is why eating raw cannabis flower will not produce much of a high, and why edible manufacturers heat their extracts during production.
The thermal conversion process is not perfectly clean, either. When CBDA is heated, it predominantly transforms into CBD, but the process can also produce trace amounts of delta-9-THC and its isomers through side reactions like isomerization and oxidation.23Journal of Analytical Science and Technology. Thermal decarboxylation of acidic cannabinoids in Cannabis species: identification of transformed cannabinoids by UHPLC-Q/TOF–MS This is one of the technical reasons why even products starting from high-CBD, low-THC hemp can sometimes end up with more THC than expected in the finished product, particularly if processing temperatures are not carefully controlled.